Navigation Links
Research offers promising new approach to treatment of lung cancer
Date:5/22/2013

CORVALLIS, Ore. Researchers have developed a new drug delivery system that allows inhalation of chemotherapeutic drugs to help treat lung cancer, and in laboratory and animal tests it appears to reduce the systemic damage done to other organs while significantly improving the treatment of lung tumors.

This advance in nanomedicine combines the extraordinarily small size of nanoparticles, existing cancer drugs, and small interfering RNA (siRNA) that shut down the ability of cancer cells to resist attack.

The combination of these forces resulted in the virtual disappearance of lung tumors in experimental animals.

Lung cancer is the leading cancer killer in both men and women. Despite advances in surgery, chemotherapy still plays a major role in its treatment. However, that treatment is constrained by the toxic effects of some drugs needed to combat it and the difficulty of actually getting those drugs into the lungs.

The findings were made by Oleh Taratula at Oregon State University and Tamara Minko and O. Garbuzenko at Rutgers University and the Cancer Institute of New Jersey. They were just published in the Journal of Controlled Release.

"Lung cancer damage is usually not localized, which makes chemotherapy an important part of treatment," said Taratula, an assistant professor in the OSU College of Pharmacy and co-author on this study. "However, the drugs used are toxic and can cause organ damage and severe side effects if given conventionally through intravenous administration.

"A drug delivery system that can be inhaled is a much more efficient approach, targeting just the cancer cells as much as possible," he said. "Other chemotherapeutic approaches only tend to suppress tumors, but this system appears to eliminate it."

A patent is being applied for on the technology, and more testing will be necessary before it is ready for human clinical trials, the researchers said.

The foundation of the new system is a "nanostructured lipid nanocarrier," tiny particles much smaller than a speck of dust that are easily inhaled and also readily attach to cancer cells. This carrier system delivers the anticancer drug. However, it also brings siRNA that makes the cancer cell more vulnerable.

Cancer cells often have two forms of resistance to drugs "pump" resistance that tends to pump the drug out of cells, and "nonpump" resistance that helps keep the cell from dying. The siRNA used in this system helps to eliminate both those forms of resistance, and leaves the cancer cell vulnerable to the drug being used to kill it.

By being inhaled, this system also avoids degradation of the chemotherapeutic agents that occurs when they are injected, researchers said. They arrive in more intact form, ready to do their job on lung cancer cells, while minimizing any side effects.

In more conventional chemotherapy for lung cancer, the drugs tend to accumulate in the liver, kidney and spleen, with much less of the drugs ever making it to the lungs. In this study, the amount of the drug delivered to the lungs rose to 83 percent with the inhalation approach, versus 23 percent with injection.


'/>"/>

Contact: Oleh Taratula
oleh.taratula@oregonstate.edu
541-737-3424
Oregon State University
Source:Eurekalert

Related medicine news :

1. Insulin Pump Therapy Provides Better Glycemic Control Among Type 1 Diabetics, According to Kantar Health Research
2. Protease Leads Feed Enzyme Market as Compared to Phytase & NSP Says New Research Report at ReportsnReports.com
3. Researchers find genetic risk factor for pulmonary fibrosis
4. Researchers find genetic tie to improved survival time for pulmonary fibrosis
5. Research at the cutting edge of knowledge
6. Fertility Clinics in Australia Industry Market Research Report Now Available from IBISWorld
7. Iowa VP for Research addresses next-generation supercomputers at congressional hearing
8. JPIDS: Releases consensus statement on research definitions for drug-resistant TB in children
9. Adeptia Featured in Recent 451 Research Impact Report
10. NYUs Movshon receives Lashley Award for his research on the neuroscience of vision
11. New multi-million dollar research center aims to solve the mystery of premature birth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... ... January 23, 2017 , ... Wooden and plastic balance boards have been around since ... balance. Kumo Board is the first and only balance board to use a ... soft and rigid at the same time as well as skill-level adjustable for all ages ...
(Date:1/23/2017)... , ... January 23, 2017 , ... Sharon Kleyne, America’s ... air to educate listeners about the benefits of making new water infrastructure a number ... said, “it’s appropriate that we expect water infrastructure to become a top priority of ...
(Date:1/23/2017)... ... 23, 2017 , ... Zachary Cattell, President of the Indiana ... industry expert at the 2017 Sector Summit hosted by Ivy Tech Community College ... Gerry Dick, will feature an employer and an association representative from five of ...
(Date:1/23/2017)... ... 2017 , ... Moisture measurement is a necessary process step ... to success. Selecting an inappropriate measurement method can cause costly errors, and poor ... equipment. Rare or expensive substances are wasted and production may even be stopped ...
(Date:1/23/2017)... California (PRWEB) , ... January 23, 2017 , ... "ProRandom is a set of camera ... to create dynamic looks in Final Cut Pro X," said Christina Austin - CEO of ... up to two layers of text with video footage. ProRandom works by using a ...
Breaking Medicine News(10 mins):
(Date:1/21/2017)... , Jan. 20, 2017 ResMed (NYSE: RMD ... ( Winter Haven, Florida ) today announced they have ... BMC and 3B will be permitted to sell their existing products ... a one-time settlement payment to 3B to close the ... not include an admission of liability or wrongdoing by any party. ...
(Date:1/21/2017)... Research and Markets has announced the addition ... Technology, Route Of Administration, End User - Forecast to 2025" ... ... at a CAGR of around 7.8% over the next decade to ... report analyzes the global markets for Advanced Drug Delivery across all ...
(Date:1/20/2017)... , Jan. 20, 2017  Ethicon Endo-Surgery, ... Megadyne Medical Products, Inc., a privately held ... markets electrosurgical tools used in operating rooms ... of Ethicon,s* advanced energy devices with Megadyne,s ... major step forward in Ethicon,s goal to ...
Breaking Medicine Technology: